Anand Parikh

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company based in TX. The American company focuses on developing precision therapies for metabolic oncology using a machine-learning platform and a metabolic regimen involving the patient's diet. Faeth's lead program combines FTH-001 and FTH-003 with an insulin suppressing regimen to slow tumor growth by shutting down the PI3K/MTOR pathway. The company's scientific founders include Drs. Lew Cantley, Sid Mukherjee, and Karen Vousden. Anand Parikh has been the CEO since incorporation.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company based in TX. The American company focuses on developing precision therapies for metabolic oncology using a machine-learning platform and a metabolic regimen involving the patient's diet. Faeth's lead program combines FTH-001 and FTH-003 with an insulin suppressing regimen to slow tumor growth by shutting down the PI3K/MTOR pathway. The company's scientific founders include Drs. Lew Cantley, Sid Mukherjee, and Karen Vousden. Anand Parikh has been the CEO since incorporation.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company based in TX. The American company focuses on developing precision therapies for metabolic oncology using a machine-learning platform and a metabolic regimen involving the patient's diet. Faeth's lead program combines FTH-001 and FTH-003 with an insulin suppressing regimen to slow tumor growth by shutting down the PI3K/MTOR pathway. The company's scientific founders include Drs. Lew Cantley, Sid Mukherjee, and Karen Vousden. Anand Parikh has been the CEO since incorporation.